Clinical Trials Browser

INDUSTRY × Breast Neoplasms × Drug Evaluation × Clear all

NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms